These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32966971)

  • 1. Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
    Wang X; Zhang H; Zhang Q; Guan M; Sheng S; Mo W; Zou M; Li J; Bi J; Tang X; Zeng H; He J; Xu G; Li P; Xue Y
    Am J Nephrol; 2020; 51(10):806-814. PubMed ID: 32966971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
    Muskiet MHA; Bunck MC; Heine RJ; Cornér A; Yki-Järvinen H; Eliasson B; Joles JA; Diamant M; Tonneijck L; van Raalte DH
    Diabetes Res Clin Pract; 2019 Jul; 153():14-22. PubMed ID: 31078666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.
    Pawaskar M; Tuttle KR; Li Q; Best JH; Anderson PW
    Ann Pharmacother; 2014 May; 48(5):571-6. PubMed ID: 24497624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
    Zhang J; Xian TZ; Wu MX; Li C; Pan Q; Guo LX
    Cardiovasc Diabetol; 2020 Apr; 19(1):48. PubMed ID: 32334592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
    Retnakaran R; Pu J; Ye C; Emery A; Kramer CK; Zinman B
    Cardiovasc Diabetol; 2023 Mar; 22(1):50. PubMed ID: 36894921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.
    Fayfman M; Galindo RJ; Rubin DJ; Mize DL; Anzola I; Urrutia MA; Ramos C; Pasquel FJ; Haw JS; Vellanki P; Wang H; Albury BS; Weaver R; Cardona S; Umpierrez GE
    Diabetes Care; 2019 Mar; 42(3):450-456. PubMed ID: 30679302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
    Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
    Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
    August P; Hardison RM; Hage FG; Marroquin OC; McGill JB; Rosenberg Y; Steffes M; Wall BM; Molitch M;
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):64-71. PubMed ID: 24178969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
    Loughlin AM; Qiao Q; Nunes AP; Öhman P; Ezzy S; Yochum L; Clifford CR; Gately R; Dore DD; Seeger JD
    Diabetes Obes Metab; 2018 Apr; 20(4):898-909. PubMed ID: 29193561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
    Taheri S; Asim M; Al Malki H; Fituri O; Suthanthiran M; August P;
    Trials; 2018 Apr; 19(1):230. PubMed ID: 29665833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.
    Retnakaran R; Ye C; Emery A; Kramer CK; Zinman B
    Nat Commun; 2022 Oct; 13(1):6109. PubMed ID: 36244997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
    Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
    Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
    Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
    Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
    Yan M; Wen Y; Yang L; Wu X; Lu X; Zhang B; Huang W; Li P
    Trials; 2016 May; 17(1):259. PubMed ID: 27216240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
    Groop PH; Cooper ME; Perkovic V; Hocher B; Kanasaki K; Haneda M; Schernthaner G; Sharma K; Stanton RC; Toto R; Cescutti J; Gordat M; Meinicke T; Koitka-Weber A; Thiemann S; von Eynatten M
    Diabetes Obes Metab; 2017 Nov; 19(11):1610-1619. PubMed ID: 28636754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.